Ding Y, Cao L, Zhu L, et al. - Due to a lack of data on tenofovir alafenamide fumarate (TAF) for preventing mother‐to‐child transmission of hepatitis B virus (HBV), researchers tested the safety and effectiveness of TAF therapy for preventing hepatitis B mother‐to‐child transmission. Mothers with chronic HBV infection, positive for hepatitis B e‐antigen and with HBV DNA > 200 000 IU/mL received TAF for preventing mother‐to‐child transmission have been recruited retrospectively from multiple centres with data collection on mother‐infant dyads up to postpartum week 24‐28. Among 71 mothers enlisted, the mean (±SD) age was 30.3 (±2.2) years. According to results, TAF effectively prevented mother‐to‐child transmission of hepatitis B for highly viraemic mothers. With 24‐28 weeks of follow up, there were no safety concerns for either mothers or infants. There have been no serious adverse effects recorded in either mothers or infants.